RNAC Company Profile and Key Details

Cartesian Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.73. This means the shares are trading above this model’s fair value.

Cartesian Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 34.24%. Wall Street analysts project EPS growth of 5.88% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $44.00 to $16.00. The high target offers 437.24% upside. The low target suggests 95.36% downside. The mean target is $36.54. This offers 346.15% upside. Cartesian Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -152.4%. The prior quarter beat by 64.04%. Over the last six quarters, Apple has recorded several small beats. These include 11.48% in May 08, 2025.

RNAC has shown mixed momentum, losing -0.55% over the past week and -19.76% over the past quarter, though year-to-date performance is up 0.28%. Short-term trend indicators are bullishly aligned (SMA20 21.62%, SMA50 16.52%, SMA200 -9.8%). The stock’s 14-day RSI is 71.57 (overbought), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -57.05% below its high and over 39.63% above its low. Average 10-day trading volume of 105.52 thousand shares is below the 3-month average of 182.97 thousand, indicating normal recent market interest.

Cartesian Therapeutics, Inc. has 29.38 million shares outstanding. The public float is 10.63 million shares, elevated short interest at 14.81% of float. This equals 1.93 million shares. The short ratio is 7.04 days. Institutional investors hold 61.53% of the float. Insiders own 52.13%. SPRINGER TIMOTHY A holds 656.51 thousand shares, Brunn Carsten has 323.53 thousand shares and Davis Blaine has 121.22 thousand shares.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) closed at $8.19 USD, losing -$0.24 (-2.85%) from the previous close of $8.43. The stock is currently mid-range between its 52-week high and low $5.60 and $11.00. With a market capitalization of about $240.63 million, Cartesian Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.62). Key stats such as the average daily volume over the past year has been around 172.07 thousand shares, in line with its 52-week average. Headquartered in Frederick, MD, Cartesian Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carsten Brunn, the company employs approximately 75 people and listed since June 22, 2016. Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.

Cartesian Therapeutics, Inc. trades at a P/E ratio of -1.4, slightly below the S&P 500 average, with a price-to-sales ratio of 165.11 and a price-to-book ratio of -1.95 indicating negative book value, which may reflect financial stress. The P/FCF stands at -3.12, also above market averages.

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) shares are flat 0.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cartesian Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.4. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $40.77, suggesting 397.8% upside. Our AI forecast model points to short-term weakness (-11.11% over two weeks), a medium-term rise (35.65% over three months), and a longer-term gain (95.12% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cartesian Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.11%, with price expected at $7.28 by September 25, 2026, within a range of $6.87 to $7.68 3-Month Outlook: Projected rise of 35.65%, reaching $11.11 by December 10, 2026, with a range of $10.37 to $11.76. 1-Year Outlook: Projected gain of 95.12%, with price at $15.98 by September 10, 2027, within a range of $0.27 to $19.46.